Intellia Therapeutics Share Price Today
(NASDAQ: NTLA)

Name: Intellia Therapeutics Share Price Today (NASDAQ: NTLA) - Intellia Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Intellia Therapeutics share price is $10.32 & ₹894.12 as on 1 Feb 2025, 2.30 'hrs' IST

$10.32

▲

-0.19

(-1.81%)

Market is closed - opens 8 PM, 03 Feb 2025

View live Intellia Therapeutics share price in Dollar and Rupees. Guide to invest in Intellia Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Intellia Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Intellia Therapeutics share price movements

Today's Low: $10.11
Today's High: $10.64
$10.32
2.03%
Downside
Day's Volatility :4.99%
Upside
3.02%
52 Weeks Low: $9.25
52 Weeks High: $34.87
$10.32
10.37%
Downside
52 Weeks Volatility :73.47%
Upside
70.4%

Intellia Therapeutics (NTLA) Returns

Period	Intellia Therapeutics Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-31.84%	-0.6%	0.0%
6 Months	-53.78%	-2.8%	0.0%
1 Year	-59.19%	3.3%	0.0%
3 Years	-89.18%	11.6%	-13.7%

Intellia Therapeutics (NTLA) Key Statistics

in dollars & INR

Previous Close	$10.51
Open	$10.58
Today's High	$10.6415
Today's Low	$10.11
Market Capitalization	$1.1B
Today's Volume	$2.1M
52 Week High	$34.87
52 Week Low	$9.25
Revenue TTM	$43.1M
EBITDA	$-527.5M
Earnings Per Share (EPS)	$-5.45
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-52.23%

How to invest in Intellia Therapeutics Stock (NTLA) from India?

It is very easy for Indian residents to invest directly in Intellia Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Intellia Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Intellia Therapeutics or NTLA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Intellia Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Intellia Therapeutics shares which would translate to 0.084 fractional shares of Intellia Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Intellia Therapeutics, in just a few clicks!

Returns in Intellia Therapeutics (NTLA) for Indian investors in Rupees

The Intellia Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Intellia Therapeutics investment value today

Current value as on today

₹45,366

Returns

₹54,634

(-54.63%)

Returns from Intellia Therapeutics Stock

₹59,193 (-59.19%)

Dollar Returns

₹4,559 (+4.56%)

Indian investors sentiment towards Intellia Therapeutics (NTLA)

-12.71%

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Investment in Intellia Therapeutics Shares from India has dropped by -12.71% over the past 30 days, indicating reduced transactional activity.

20%

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Search interest for Intellia Therapeutics Stock from India on INDmoney has increased by 20% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Intellia Therapeutics

ARK Investment Management LLC
12.03%
BlackRock Inc
9.60%
Vanguard Group Inc
9.45%
State Street Corp
5.05%
Deep Track Capital, LP
4.86%
Sumitomo Mitsui Trust Group Inc
3.09%

Analyst Recommendation on Intellia Therapeutics

Buy

79%Buy

20%Hold

0%Sell

Based on 34 Wall street analysts offering stock ratings for Intellia Therapeutics(by analysts ranked 0 to 5 stars)

Based on 34 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Intellia Therapeutics Stock (NTLA)

What analysts predicted

Upside of 392.26%

Target:

$50.80

Current:

$10.32

Insights on Intellia Therapeutics Stock (Ticker Symbol: NTLA)

Price Movement
In the last 6 months, NTLA stock has moved down by -58.9%
Increasing Revenue
Revenue is up for the last 2 quarters, 6.95M → 9.11M (in $), with an average increase of 23.6% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -146.97M → -135.71M (in $), with an average increase of 8.3% per quarter
NTLA vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 55.1% return, outperforming this stock by 114.2%
NTLA vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 87.2% return, outperforming this stock by 176.9%
Price to Sales
ForNTLA every $1 of sales, investors are willing to pay $23.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.4 for every $1 of sales.

NTLA Intellia Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$30.4M	↑ 16.53%
Net Income	$-85.3M	↑ 26.35%
Net Profit Margin	-280.42%	↓ 21.8%

	FY19	Y/Y Change
Revenue	$43.1M	↑ 41.63%
Net Income	$-92.7M	↑ 8.62%
Net Profit Margin	-215.06%	↑ 65.36%

	FY20	Y/Y Change
Revenue	$58.0M	↑ 34.55%
Net Income	$-125.6M	↑ 35.46%
Net Profit Margin	-216.52%	↓ 1.46%

	FY21	Y/Y Change
Revenue	$33.1M	↓ 43.01%
Net Income	$-259.7M	↑ 106.83%
Net Profit Margin	-785.76%	↓ 569.24%

	FY22	Y/Y Change
Revenue	$52.1M	↑ 57.69%
Net Income	$-490.2M	↑ 88.75%
Net Profit Margin	-940.52%	↓ 154.76%

	FY23	Y/Y Change
Revenue	$36.3M	↓ 30.4%
Net Income	$-481.2M	↓ 1.84%
Net Profit Margin	-1.3K%	↓ 385.99%

	Q2 FY23	Q/Q Change
Revenue	$13.6M	↑ 7.84%
Net Income	$-123.7M	↑ 33.94%
Net Profit Margin	-909.82%	↓ 177.28%

	Q3 FY23	Q/Q Change
Revenue	$12.0M	↓ 11.78%
Net Income	$-122.2M	↓ 1.18%
Net Profit Margin	-1.0K%	↓ 109.39%

	Q4 FY23	Q/Q Change
Revenue	$-1.9M	↓ 115.99%
Net Income	$-132.2M	↑ 8.13%
Net Profit Margin	6.9K%	↑ 7913.37%

	Q1 FY24	Q/Q Change
Revenue	$28.9M	↓ 1609.39%
Net Income	$-107.4M	↓ 18.71%
Net Profit Margin	-371.3%	↓ 7265.46%

	Q2 FY24	Q/Q Change
Revenue	$7.0M	↓ 75.96%
Net Income	$-147.0M	↑ 36.8%
Net Profit Margin	-2.1K%	↓ 1741.32%

	Q3 FY24	Q/Q Change
Revenue	$9.1M	↑ 30.96%
Net Income	$-135.7M	↓ 7.66%
Net Profit Margin	-1.5K%	↑ 623.08%

	FY18	Y/Y Change
Profit	$30.4M	↑ 16.53%

	FY19	Y/Y Change
Profit	$-65.3M	↓ 314.6%

	FY20	Y/Y Change
Profit	$58.0M	↓ 188.8%

	FY21	Y/Y Change
Profit	$33.1M	↓ 43.01%

	FY22	Y/Y Change
Profit	$44.5M	↑ 34.78%

	FY23	Y/Y Change
Profit	$27.3M	↓ 38.72%

	Q2 FY23	Q/Q Change
Profit	$11.4M	↑ 8.22%

	Q3 FY23	Q/Q Change
Profit	$9.7M	↓ 15.07%

	Q4 FY23	Q/Q Change
Profit	$-4.4M	↓ 145.18%

	Q1 FY24	Q/Q Change
Profit	$26.4M	↓ 702.85%

	Q2 FY24	Q/Q Change
Profit	$4.4M	↓ 83.51%

	Q3 FY24	Q/Q Change
Profit	$9.1M	↑ 109.06%

	FY18	Y/Y Change
Operating Cash Flow	$-61.3M	↓ 6.16%
Investing Cash Flow	$-260.8M	↑ 2484.3%
Financing Cash Flow	$40.2M	↓ 71.87%

	FY19	Y/Y Change
Operating Cash Flow	$-103.2M	↑ 68.54%
Investing Cash Flow	$25.2M	↓ 109.65%
Financing Cash Flow	$76.4M	↑ 90.05%

	FY20	Y/Y Change
Operating Cash Flow	$-49.9M	↓ 51.65%
Investing Cash Flow	$-214.5M	↓ 951.95%
Financing Cash Flow	$371.8M	↑ 386.41%

	FY21	Y/Y Change
Operating Cash Flow	$-225.0M	↑ 350.85%
Investing Cash Flow	$-550.8M	↑ 156.79%
Financing Cash Flow	$736.7M	↑ 98.15%

	FY22	Y/Y Change
Operating Cash Flow	$-333.3M	↑ 48.11%
Investing Cash Flow	$160.3M	↓ 129.11%
Financing Cash Flow	$583.0M	↓ 20.87%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-90.3M	↓ 17.38%
Investing Cash Flow	$-34.5M	↓ 71.75%
Financing Cash Flow	$2.5M	↑ 13.28%

Intellia Therapeutics Technicals Summary

Sell

Neutral

Buy

Intellia Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Intellia Therapeutics (NTLA) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Intellia Therapeutics Inc.	-15.55%	-53.78%	-59.19%	-89.18%	-15.89%
Biontech Se	7.35%	57.95%	33.59%	-31.3%	308.89%
Regeneron Pharmaceuticals, Inc.	-5.9%	-37.18%	-28.8%	8.05%	97.29%
Vertex Pharmaceuticals Incorporated	13.78%	-3.19%	8.71%	82.07%	100.29%
Alnylam Pharmaceuticals, Inc.	16.13%	2.38%	56.77%	86.78%	136.62%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Intellia Therapeutics Inc.	NA	NA	-0.1	-5.27	-0.52	-0.28	NA	9.46
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	16.89	16.89	1.06	44.96	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.15	0.49	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Intellia Therapeutics Inc.	Buy	$1.1B	-15.89%	NA	0.0%
Biontech Se	Buy	$29.0B	308.89%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.1B	97.29%	16.89	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$112.9B	100.29%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.7B	136.62%	NA	-15.86%

Intellia Therapeutics Dividend announcements

Intellia Therapeutics Earnings
Intellia Therapeutics’s price-to-earnings ratio stands at None
Read More

About Intellia Therapeutics

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Organization	Intellia Therapeutics
Employees	526
CEO	Dr. John M. Leonard M.D.
Industry	Health Technology

Management People of Intellia Therapeutics

Name	Title
Dr. John M. Leonard M.D.	President, CEO & Director
Mr. James E. Basta Esq., J.D.	Executive VP, General Counsel & Corporate Secretary
Dr. Laura Sepp-Lorenzino Ph.D.	Special Advisor to the Chief Executive Officer
Dr. David Lebwohl M.D.	Executive VP & Chief Medical Officer
Mr. Nessan Bermingham Ph.D.	Founder & Member of Scientific Advisor Board
Dr. Rachel E. Haurwitz Ph.D.	Co-Founder
Dr. Andrew May Ph.D.	Founder and Member of Scientific Advisor Board
Dr. Jennifer A. Doudna Ph.D.	Founder & Member of Scientific Advisor Board
Dr. Derrick J. Rossi Ph.D.	Founder & Member of Scientific Advisor Board
Dr. Rodolphe Barrangou M.B.A., Ph.D.	Founder & Member of Scientific Advisor Board

Important FAQs about investing in NTLA Stock from India :

What is Intellia Therapeutics share price today?

Intellia Therapeutics share price today stands at $10.32, Open: $10.58 ; Previous Close: $10.51 ; High: $10.64 ; Low: $10.11 ; 52 Week High: $34.87 ; 52 Week Low: $9.25.

The stock opens at $10.58, after a previous close of $10.51. The stock reached a daily high of $10.64 and a low of $10.11, with a 52-week high of $34.87 and a 52-week low of $9.25.

Can Indians buy Intellia Therapeutics shares?

Yes, Indians can invest in the Intellia Therapeutics (NTLA) from India.

With INDmoney, you can buy Intellia Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Intellia Therapeutics at zero transaction cost.

How can I buy Intellia Therapeutics shares from India?

It is very easy to buy Intellia Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Intellia Therapeutics (NTLA) be purchased?

Yes, you can buy fractional shares of Intellia Therapeutics with INDmoney app.

What are the documents required to start investing in Intellia Therapeutics stocks?

To start investing in Intellia Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.